Eli Lilly and Co (LLY.N)
LLY.N on New York Stock Exchange
79.91USD
1:06am IST
79.91USD
1:06am IST
Change (% chg)
$0.85 (+1.08%)
$0.85 (+1.08%)
Prev Close
$79.06
$79.06
Open
$79.39
$79.39
Day's High
$79.98
$79.98
Day's Low
$79.17
$79.17
Volume
373,666
373,666
Avg. Vol
1,306,940
1,306,940
52-wk High
$89.07
$89.07
52-wk Low
$73.70
$73.70
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2017 | Dec '17 | 6,160.70 | 0.246 |
| Sep '17 | 5,658.00 | 0.526 | |
| Jun '17 | 5,824.30 | 0.954 | |
| Mar '17 | 5,228.30 | -0.105 | |
| FY 2016 | Dec '16 | 5,760.50 | 0.725 |
| Sep '16 | 5,191.70 | 0.733 | |
| Jun '16 | 5,404.80 | 0.705 | |
| Mar '16 | 4,865.10 | 0.414 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 12 | 5,894.49 | 6,070.00 | 5,754.85 | 5,622.75 |
| Quarter Ending Sep-18 | 12 | 5,835.26 | 5,981.00 | 5,630.00 | 5,442.25 |
| Year Ending Dec-18 | 18 | 23,396.60 | 23,841.00 | 23,105.00 | 22,126.00 |
| Year Ending Dec-19 | 18 | 23,848.90 | 24,930.00 | 22,784.50 | 23,286.80 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 14 | 1.25 | 1.36 | 1.15 | 1.11 |
| Quarter Ending Sep-18 | 14 | 1.26 | 1.44 | 1.17 | 1.09 |
| Year Ending Dec-18 | 20 | 4.87 | 4.95 | 4.64 | 4.38 |
| Year Ending Dec-19 | 20 | 5.31 | 5.70 | 5.06 | 4.95 |
| LT Growth Rate (%) | 7 | 11.59 | 14.14 | 9.20 | 12.44 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 37.74 | 30.95 | 32.74 | |
| P/E High - Last 5 Yrs. | 37.29 | 40.70 | 45.72 | |
| P/E Low - Last 5 Yrs. | 11.81 | 23.63 | 24.22 | |
| Beta | 0.35 | 0.89 | 0.88 | |
| Price to Sales (TTM) | 4.36 | 3.94 | 5.71 | |
| Price to Book (MRQ) | 6.80 | 4.80 | 5.37 | |
| Price to Tangible Book (MRQ) | 18.20 | 5.61 | 6.95 | |
| Price to Cash Flow (TTM) | 24.17 | 22.91 | 23.32 | |
| % Owned Institutions | 77.89 | 1.21 | 2.17 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | 2.39 | 1.56 | 1.50 | |
| Dividend Yield - 5 Year Avg | 3.03 | 1.57 | 1.51 | |
| Dividend 5 Year Growth Rate | 0.80 | 4.47 | 5.32 | |
| Payout Ratio(TTM) | 92.77 | 45.35 | 43.29 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 7.76 | 3.69 | 9.21 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 6.79 | 4.83 | 5.69 | |
| Sales - 5 Yr. Growth Rate | -2.66 | 10.08 | 10.32 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 35.20 | 16.36 | 19.36 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -0.54 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -7.96 | 9.87 | 10.76 | |
| Capital Spending - 5 Yr. Growth Rate | -8.40 | 15.52 | 15.47 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 1.01 | 2.12 | 2.19 |
| Current Ratio (MRQ) | 1.39 | 2.90 | 2.98 |
| LT Debt to Equity (MRQ) | 69.98 | 9.88 | 12.18 |
| Total Debt to Equity (MRQ) | 87.31 | 13.86 | 16.45 |
| Interest Coverage (TTM) | 46.20 | 35.89 | 32.81 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 73.89 | 54.81 | 54.44 | |
| Gross Margin - 5 Yr. Avg. | 76.22 | 52.15 | 52.20 | |
| EBITD Margin (TTM) | 27.24 | -- | -- | |
| EBITD - 5 Yr. Avg | 26.57 | 18.57 | 10.96 | |
| Operating Margin (TTM) | 14.23 | 14.36 | 4.73 | |
| Operating Margin - 5 Yr. Avg. | 17.60 | 14.52 | 6.40 | |
| Pre-Tax Margin (TTM) | 14.47 | 14.82 | 5.57 | |
| Pre-Tax Margin - 5 Yr. Avg. | 19.21 | 14.90 | 6.81 | |
| Net Profit Margin (TTM) | 11.12 | 11.08 | 1.87 | |
| Net Profit Margin - 5 Yr. Avg. | 15.31 | 11.20 | 3.09 | |
| Effective Tax Rate (TTM) | 23.16 | 23.16 | 23.04 | |
| Effective Tax Rate - 5 Yr. Avg. | 20.29 | 23.42 | 23.96 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 524,236 | 938,079,949 | 846,830,978 | |
| Net Income/Employee (TTM) | 58,297 | 110,368,367 | 99,616,195 | |
| Receivable Turnover (TTM) | 5.30 | 5.63 | 5.78 | |
| Inventory Turnover (TTM) | 1.42 | 2.59 | 3.35 | |
| Asset Turnover (TTM) | 0.57 | 0.95 | 0.92 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 6.32 | 11.40 | 10.95 | |
| Return on Assets - 5 Yr. Avg. | 9.18 | 12.91 | 12.31 | |
| Return on Investment (TTM) | 8.49 | 14.84 | 14.38 | |
| Return on Investment - 5 Yr. Avg. | 12.32 | 16.88 | 16.10 | |
| Return on Equity (TTM) | 17.03 | 16.34 | 16.07 | |
| Return on Equity - 5 Yr. Avg. | 21.43 | 17.98 | 17.39 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 6.33 | -2.81 | -2.66 |
| EPS (TTM) % | 14.09 | -15.80 | -7.96 |
| Dividend % | 2.00 | 1.34 | 0.80 |
Note: Units in Millions of US Dollars
Performance for Eli Lilly and Co
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 5.02 | 1.40 | 99 | 23 |
| 13 Week | 5.82 | 0.67 | 99 | 34 |
| 26 Week | 2.06 | -5.70 | 99 | 29 |
| 52 Week | 6.89 | -9.41 | 99 | 12 |
| YTD | 18.40 | 3.98 | 99 | 25 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Lilly And Sigilon Therapeutics Announce Strategic Collaboration To Develop Encapsulated Cell Therapies
- BRIEF-Tasly Pharma's Unit Signs Licensing Agreement On Diabetes Medicine With Eli Lilly
- U.S. judge dismisses FTC antitrust lawsuit against Shire unit
- CVS appoints former Eli Lilly CFO as president of PBM business
- BRIEF-Eli Lilly CEO David Ricks' Total Compensation For 2017 Was $15.8 Mln
Institutional Holders
| % Shares Owned: | 79.76% |
| # of Holders: | 1,750 |
| Total Shares Held: | 871,583,615 |
| 3 Mo. Net Change: | 13,045 |
| # New Positions: | 19 |
| # Closed Positions: | 29 |
| # Increased Positions: | 147 |
| # Reduced Positions: | 149 |
| # Net Buyers: | -2 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.